Osimertinib works by inhibiting abnormal signaling from specific forms of the epidermal growth factor receptor (EGFR) found in certain lung cancers.
Simple explanation
Some NSCLC tumors contain genetic changes that make EGFR signaling abnormally active. EGFR is a cell-surface receptor involved in signals controlling cell growth and survival.
In EGFR-mutated cancer, excessive signaling can contribute to uncontrolled tumor growth.
Osimertinib enters cells and inhibits mutant EGFR activity. By reducing the signaling generated by these abnormal receptors, the medicine can interfere with pathways that support cancer-cell survival and proliferation.
Detailed mechanism
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor. It irreversibly inhibits mutant EGFR forms through covalent binding and has activity against both sensitizing EGFR mutations and the T790M resistance mutation.
The common sensitizing alterations relevant to approved uses include:
- EGFR exon 19 deletions
- EGFR exon 21 L858R substitution
- Other activating EGFR alterations in certain regulatory settings
- EGFR T790M in previously treated disease under applicable indications
Why T790M matters
Earlier-generation EGFR TKIs can lose effectiveness when tumor cells acquire a secondary EGFR T790M mutation. T790M alters the EGFR kinase domain in a way that can reduce sensitivity to earlier inhibitors.
Osimertinib was specifically developed to address this resistance mechanism. Its clinical development therefore represents an important step in the evolution of EGFR-targeted therapy.
Selectivity for mutant EGFR
Osimertinib was designed to have greater selectivity for mutant EGFR than for wild-type EGFR. This pharmacologic profile helped distinguish it from earlier EGFR inhibitors, although treatment still produces adverse effects because EGFR signaling has physiological roles in normal tissues.
Central nervous system activity
A clinically important feature of osimertinib is its ability to penetrate the blood-brain barrier. Published research indicates that osimertinib has meaningful CNS activity and can help control intracranial disease in appropriately selected EGFR-mutated NSCLC patients.
Resistance can still develop
Targeted therapy does not guarantee permanent tumor control. Cancer cells can acquire additional molecular changes or activate alternative signaling pathways that allow growth despite EGFR inhibition.
Reported mechanisms of acquired resistance to osimertinib include EGFR-dependent alterations such as C797S and EGFR-independent mechanisms involving bypass signaling, gene fusions and phenotypic changes.
Key concept
Osimertinib is therefore best understood as a molecularly targeted treatment, not a general-purpose lung cancer medicine. Its usefulness depends on the biology of the tumor and the clinical context.